CLAIMS

What is claimed is:

1. A method of inhibiting CRTH2 in a subject in need of CRTH2 inhibition, comprising administering to the subject an effective amount of a compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof, wherein:

Ring **A** is an optionally substituted monocyclic aromatic ring;

R is $-X_1-R^1$;

R^x is $-X_2-R^4$, and R^3 is an optionally substituted, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group; or $-NR^xR^3$, taken together, is an optionally substituted non-aromatic nitrogen containing heterocyclic group;

X is $-C(O)-$ or $-C(R^2)_2-$;

X_1 and X_2 are each independently a bond, S(O), $S(O)_2$, C(O) or C(O)NH;

R^1 is H or an optionally substituted, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

provided that when X_1 is a bond, SO or SO_2, then R^1 is not H;

each R^2 is independently H, $-X_4-R^8$ or an optionally substituted, aliphatic group, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

R^4 is H, $-X_6-R^{10}$ or an optionally substituted, aliphatic group, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

provided that when X_2 is a bond, SO or SO_2, then R^4 is not H;

X_4 and X_6 are each independently a straight or branched hydrocarbyl group optionally substituted with one or more groups selected from the group consisting of halo, -OH, =O, C_1-C_3 alkoxy, nitro and cyano;

R^5 and R^6 are each independently H or C_1-C_3 alkyl; and

R^8 and R^{10} are each independently H, -C(O)OR' or an optionally substituted, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

where,

the optional substituents on the aliphatic group, the cycloaliphatic group or the non-aromatic heterocyclic group are one to three groups each independently selected from the group consisting of halo, R^{11}, =O, =S, =NNHR*, =NN(R*)$_2$, =NNHC(O)R*, =NNHCO$_2$(alkyl), =NNHSO$_2$ (alkyl) and =NR*;

the optional substituents on unsaturated carbon atoms of the aromatic group is R^{11};

the optional substituents on a nitrogen atom of the aromatic group or the nitrogen atom of the non-aromatic nitrogen containing heterocyclic group are one to three groups each independently selected from the group consisting of R^+, $N(R^+)_2$, -C(O)R^+, -CO$_2$ R^+, -C(O)C(O)R^+, -C(O)CH$_2$C(O)R^+, -SO$_2$ R^+, -SO$_2$ $N(R^+)_2$, -C(=S)$N(R^+)_2$, -C(=NH)-$N(R^+)_2$ and -NR^+ SO$_2$$R^+$;

R^{11} is one to four substituents each independently selected from the group consisting of halo, R°, -OH, -OR°, -SH, -SR°, 1,2-methylenedioxy, 1,2-ethylenedioxy, protected -OH, phenyl, [R^{12}]-phenyl, -O(phenyl), -O([R^{12}]-phenyl), -CH$_2$(phenyl), -CH$_2$([R^{12}]-phenyl), -CH$_2$CH$_2$(phenyl), -CH$_2$CH$_2$([R^{12}]-phenyl), -NO$_2$, -CN, -N(R')$_2$, -NR'CO$_2$R°, -NR'C(O)R°, -NR'NR'C(O)R°, -N(R')C(O)N(R')$_2$, -NR'NR'C(O)N(R')$_2$, -NR'NR'CO$_2$R°, -C(O)C(O)R°, -C(O)CH$_2$C(O)R', -CO$_2$R', -C(O)R°, -C(O)N(R')$_2$, -OC(O)N(R')$_2$, -S(O)$_2$R°, -SO$_2$N(R')$_2$, -S(O)R', -NR'SO$_2$N(R')$_2$, -NR'SO$_2$R°, -C(=S)N(R')$_2$, -(CH$_2$)$_y$N(R')$_2$, -C(=NH)-N(R')$_2$, -(CH$_2$)$_y$C(O)N(R')$_2$, -(CH$_2$)$_y$NHC(O)R' or -(CH$_2$)$_y$NHC(O)CH(V-R')(R');

R' is H, R°, -CO$_2$R°, -SO$_2$R° or -C(O)R°;

y is 0-6;

V is C_1-C_6 alkylene;

each R* is independently H, an aliphatic group or an aliphatic group substituted with R^{12};

R^+ is H, phenyl, [R^{12}]-phenyl, -O(phenyl), -O([R^{12}]-phenyl), -CH_2(phenyl), -CH_2([R^{12}]-phenyl), a heteroaryl group, a non-aromatic heterocyclic group, an aliphatic group or an aliphatic group substituted with R^{12};

R^o is an aliphatic group, a cycloaliphatic group, an aromatic group, an aralkyl group or a non-aromatic heterocyclic group, each group being optionally substituted with R^{12};

R^{12} is one to four substituents each independently selected from the group consisting of halo, C_1-C_6 alkyl, (halo)$_r$$C_1$-$C_6$ alkyl, C_3-C_8 cycloalkyl, (halo)$_r$$C_3$-$C_8$ cycloalkyl, -CN, -CF_3, -CHF_2, -CH_2F, -OCF_3, -$OCHF_2$, -OCH_2F, -OR', -OR^{13}C(O)R', -C(O)OR', -C(O)N(R^{16})$_2$, -N(R^{16})$_2$, -NO_2, -NR^{16}C(O)R', -NR^{16}C(O)OR', -NR^{16}C(O)N(R^{16})$_2$, -$NR^{16}SO_2R^{17}$, -S(O)$_q$$R^{17}$, -$R^{13}NR^{16}$C(O)R', -$R^{13}$C(O)R', -$R^{13}NR^{16}$C(O)OR', tetrazolyl, imidazolyl or oxadiazolyl;

R^{13} is C_1-C_6 alkyl or C_3-C_8 cycloalkyl;

each R^{16} is independently R' or benzyl;

R^{17} is R^{13} or -CF_3;

q is 0-2; and

r is 1-3.

2. The method of Claim 1 wherein:

Ring A is phenyl or [R^{11}]-phenyl;

X is -CHR^2-;

R^x is -X_2-R^4;

R^1 and R^3 are each independently an optionally substituted, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

R^2 is H or an optionally substituted, C_1-C_4 alkyl group, C_1-C_4 alkyl alkoxymethylene group or C_3-C_6 cycloalkyl group;

R^4 is an optionally substituted, aliphatic group, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group; and

R^5 and R^6 are each H.

3. The method of Claim 2 wherein R^3 is an optionally substituted aromatic group.

4. The method of Claim 3 wherein the compound is represented by the following structural formula:



where Ring **A**, R^1, R^2 and R^4 are each independently defined in Claim 2.

5. The method of Claim 4 wherein:

R^1 is H or an optionally substituted, cycloalkyl group, aromatic group or non-aromatic heterocyclic group;

R^3 is phenyl or [R^{11}]-phenyl;

R^4 is H, $-CH_2C(O)R^{14}$, $-CH_2R^{15}$, $-CH_2OR^{14}$ or an optionally substituted, C_1-C_3 alkyl group, cycloalkyl group, aromatic group or non-aromatic heterocyclic group;

R^{14} is H or an optionally substituted, alkyl group, aromatic group, cycloalkyl group or non-aromatic heterocyclic group; and

R^{15} is an optionally substituted, aromatic group, cycloalkyl group or non-aromatic heterocyclic group;

where R^{11} and the optional substituents are each independently defined in Claim 1.

6. The method of Claim 1 wherein Ring **A** is thiophene, furan, pyridine, pyrazole, pyrrole, [2,3]pyrimidine, [3,4]pyrimidine, [4,5]pyrimidine, [5,6]pyrimidine, oxazole, isoxazole or 1,2,3-triazole, each group being optionally substituted with R^{11}.

7. The method of Claim 6 wherein:

X is $-CHR^2-$;

R^x is $-X_2-R^4$;

R^1 and R^3 are each independently an optionally substituted, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

R^2 is H or an optionally substituted, C_1-C_4 alkyl group, C_1-C_4 alkyl alkoxymethylene group or C_3-C_6 cycloalkyl group;

R^4 is an optionally substituted, aliphatic group, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group; and

R^5 and R^6 are each H.

8. A compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:

Ring **A** is an optionally substituted monocyclic aromatic ring;

R is $-X_1-R^1$;

R^x is $-X_2-R^4$, and R^3 is an optionally substituted aromatic group; or $-NR^xR^3$, taken together, is an optionally substituted non-aromatic nitrogen containing heterocyclic group;

X is -C(O)- or -$C(R^2)_2$-;

X_1 and X_2 are each independently a bond, S(O), $S(O)_2$, C(O) or C(O)NH;

R^1 is H or an optionally substituted, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

provided that when X_1 is a bond, SO or SO_2, then R^1 is not H;

each R^2 is independently H, -X_4-R^8 or an optionally substituted, aliphatic group, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

R^4 is H, -X_6-R^{10} or an optionally substituted, aliphatic group, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

provided that when X_2 is a bond, SO or SO_2, then R^4 is not H;

X_4 and X_6 are each independently a straight or branched hydrocarbyl group optionally substituted with one or more groups selected from the group consisting of halo, -OH, =O, C_1-C_3 alkoxy, nitro and cyano;

R^5 and R^6 are each independently H or C_1-C_3 alkyl; and

R^8 and R^{10} are each independently H, -C(O)OR' or an optionally substituted, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

where,

the optional substituents on the aliphatic group, the cycloaliphatic group or the non-aromatic heterocyclic group are one to three groups each independently selected from the group consisting of halo, R^{11}, =O, =S, =NNHR*, =$NN(R^*)_2$, =NNHC(O)R*, =$NNHCO_2$(alkyl), =$NNHSO_2$ (alkyl) and =NR*;

the optional substituents on unsaturated carbon atoms of the aromatic group is R^{11};

the optional substituents on a nitrogen atom of the aromatic group or the nitrogen atom of the non-aromatic nitrogen containing heterocyclic group are one to three groups each independently selected from the group consisting of R^+, $N(R^+)_2$, -$C(O)R^+$, -CO_2R^+, -$C(O)C(O)R^+$, -$C(O)CH_2C(O)R^+$, -SO_2R^+, -$SO_2N(R^+)_2$, -$C(=S)N(R^+)_2$, -C(=NH)-$N(R^+)_2$ and -$NR^+SO_2R^+$;

R^{11} is one to four substituents each independently selected from the group consisting of halo, R^o, -OH, -OR^o, -SH, -SR^o, 1,2-methylenedioxy, 1,2-

ethylenedioxy, protected -OH, phenyl, [R^{12}]-phenyl, -O(phenyl), -O([R^{12}]-phenyl), -CH_2(phenyl), -CH_2([R^{12}]-phenyl), -CH_2CH_2(phenyl), -CH_2CH_2([R^{12}]-phenyl), -NO_2, -CN, -N(R')$_2$, -NR'CO_2R^o, -NR'C(O)R^o, -NR'NR'C(O)R^o, -N(R')C(O)N(R')$_2$, -NR'NR'C(O)N(R')$_2$, -NR'NR'CO_2R^o, -C(O)C(O)R^o, -$C(O)CH_2C(O)R'$, -CO_2R', -C(O)R^o, -C(O)N(R')$_2$, -OC(O)N(R')$_2$, -$S(O)_2R^o$, -SO_2N(R')$_2$, -S(O)R', -NR'SO_2N(R')$_2$, -NR'SO_2R^o, -C(=S)N(R')$_2$, -$(CH_2)_y$N(R')$_2$, -C(=NH)-N(R')$_2$, -$(CH_2)_y$C(O)N(R')$_2$, -$(CH_2)_y$NHC(O)R' or -$(CH_2)_y$NHC(O)CH(V-R')(R');

R' is H, R^o, -CO_2R^o, -SO_2R^o or -C(O)R^o;

y is 0-6;

V is C_1-C_6 alkylene;

each R* is independently H, an aliphatic group or an aliphatic group substituted with R^{12};

R^+ is H, phenyl, [R^{12}]-phenyl, -O(phenyl), -O([R^{12}]-phenyl), -CH_2(phenyl), -CH_2([R^{12}]-phenyl), a heteroaryl group, a non-aromatic heterocyclic group, an aliphatic group or an aliphatic group substituted with R^{12};

R^o is an aliphatic group, a cycloaliphatic group, an aromatic group, an aralkyl group or a non-aromatic heterocyclic group, each group being optionally substituted with R^{12};

R^{12} is one to four substituents each independently selected from the group consisting of halo, C_1-C_6 alkyl, (halo)$_r$$C_1$-$C_6$ alkyl, C_3-C_8 cycloalkyl, (halo)$_r$$C_3$-$C_8$ cycloalkyl, -CN, -CF_3, -CHF_2, -CH_2F, -OCF_3, -$OCHF_2$, -OCH_2F, -OR', -OR^{13}C(O)R', -C(O)OR', -C(O)N(R^{16})$_2$, -N(R^{16})$_2$, -NO_2, -NR^{16}C(O)R', -NR^{16}C(O)OR', -NR^{16}C(O)N(R^{16})$_2$, -$NR^{16}SO_2R^{17}$, -S(O)$_q$$R^{17}$, -$R^{13}NR^{16}$C(O)R', -$R^{13}$C(O)R', -$R^{13}NR^{16}$C(O)OR', tetrazolyl, imidazolyl or oxadiazolyl;

R^{13} is C_1-C_6 alkyl or C_3-C_8 cycloalkyl;

each R^{16} is independently R' or benzyl;

R^{17} is R^{13} or -CF_3;

q is 0-2; and

r is 1-3;

provided that the compound is not 2-methyl-N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(2-methyl-1-oxobutyl)-4-quinolinyl]-butamide; N-(1-Acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-heptamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxo-3-phenylpropyl)-4-quinolinyl]-benzenepropanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(3-nitrobenzoyl)-4-quinolinyl]- hexanamide; N-[1,1'-biphenyl]-3-yl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]-acetamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(4-nitrophenyl)-heptanamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(4-methoxyphenyl)-2-methyl- propanamide; N-[1-(4-fluorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl- butanamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]-pentanamide; 2-ethyl-N-[1-(2-ethyl-1-oxobutyl)-1,2,3,4-tetrahydro-2,8-dimethyl-4-quinolinyl]-N-(2-methylphenyl)-butanamide; N-[1-[(4-fluorophenyl)acetyl]-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl- propanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(4-nitrobenzoyl)-4-quinolinyl]-octanamide; N-cyclohexyl-4-[(cyclohexylamino)carbonyl]phenylamino]-3,4-dihydro-2-methyl-1(2H)-quinolinecarboxamide; N-[1-(4-ethylbenzoyl)-1,2,3,4-tetrahydro-2,8-dimethyl-4-quinolinyl]-N-(2-methylphenyl)-3-(4-nitrophenyl)- 2-propenamide; 3-(4-methoxyphenyl)-N-phenyl-N-[1,2,3,4-tetrahydro-1-[3-(4-methoxyphenyl)-1-oxo-2-propenyl]-2-methyl-4-quinolinyl]-2-propenamide; 4-[(ethoxyoxoacetyl)phenylamino]-3,4-dihydro-2-methyl-∀-oxo-ethyl ester-1(2H)-quinolineacetic acid; N-[1-(3-cyclohexyl-1-oxopropyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl- cyclohexanepropanamide; 4-(acetylphenylamino)-3,4-dihydro-2-methyl-gamma-oxo-1(2H)-quinolinepentanoic acid; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-2,2-dimethyl-N-phenyl- propanamide; N-(1-benzoyl-6-bromo-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl- pentanamide; N-[1-(2-furanylcarbonyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl- acetamide; 2-methyl-N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]- propanamide; N-[1-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)acetyl]-1,2,3,4-tetrahydro-2-methyl-4-

quinolinyl]-N-phenyl-acetamide; 2,2,2-trifluoro-N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]- acetamide; 2-ethyl-N-[1-(2-ethyl-1-oxobutyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl- butanamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(3-methoxyphenyl)-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxohexyl)-4-quinolinyl]- acetamide; N-(1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-2-thiophenecarboxamide; N-[1-(2-fluorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl- hexanamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]- hexanamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]- hexanamide; N-[1-(cyclopropylcarbonyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-cyclopropanecarboxamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(4-methylphenyl)- acetamide; 2-methyl-N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(2-methyl-1-oxopropyl)-4-quinolinyl]- propanamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]- 2-thiophenecarboxamide; 1-(3,5-dinitrobenzoyl)-N-formyl-1,2,3,4-tetrahydro-2-methyl-N-phenyl-4-quinolinamine; N-[1-(4-chloro-3-nitrobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl- acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(3-nitrobenzoyl)-4-quinolinyl]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]- hexanamide; N-[1-(2-furanylcarbonyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-2-furancarboxamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxopropyl)-4-quinolinyl]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-[3-(4-methoxyphenyl)-1-oxo-2-propenyl]-2-methyl-4-quinolinyl]-acetamide; 3-(2-furanyl)-N-[1-[3-(2-furanyl)-1-oxo-2-propenyl]-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-2-propenamide; N-[1-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxo-3-phenylpropyl]-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-octanamide; N-[1-(3-chlorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide; Relative stereochemistry N-phenyl-N-[(2R,4S)-1,2,3,4-tetrahydro-2-methyl-1-(1-oxopropyl)-4-quinolinyl]- acetamide; Relative stereochemistry N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-2-methyl-N-

phenyl-propanamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-hexanamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-propanamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-heptanamide; Relative stereochemistry N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-2,2-dimethyl-N-phenyl-propanamide; N-[1-(3-fluorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide; N-[1-[4-(1,1-dimethylethyl)benzoyl]-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide; N-(1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-2-methyl-N-phenyl- propanamide; 2,2,2-trifluoro-N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(trifluoroacetyl)-4-quinolinyl]- acetamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-2,2-dimethyl-N-phenyl-propanamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-butanamide; Relative stereochemistry N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide; Relative stereochemistry N-phenyl-N-[(2R,4S)-1,2,3,4-tetrahydro-2-methyl-1-(1-oxoheptyl)-4-quinolinyl]-acetamide; Relative stereochemistry N-phenyl-N-[(2R,4S)-1,2,3,4-tetrahydro-2-methyl-1-(1-oxohexyl)-4-quinolinyl]-acetamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-pentanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxo-3-phenyl-2-propenyl)-4-quinolinyl]-acetamide; Relative stereochemistry N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-heptanamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide; Relative stereochemistry N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-pentanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)-4-quinolinyl]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxopropyl)-4-quinolinyl]- propanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(2-thienylcarbonyl)-4-quinolinyl]- acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]- 2-furancarboxamide; N-phenyl-N-

[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]- acetamide; N-[1-(3,5-dinitrobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(4-nitrobenzoyl)-4-quinolinyl]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(2-iodobenzoyl)-2-methyl-4-quinolinyl]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(2-methyl-1-oxopropyl)-4-quinolinyl]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-[(4-methylphenyl)sulfonyl]-4-quinolinyl]- acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-[(4-nitrophenyl)methyl]-4-quinolinyl]- acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]-acetamide; N-(1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-butanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxobutyl)-4-quinolinyl]- acetamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-hexanamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-pentanamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-propanamide; 1-benzoyl-1,2,3,4-tetrahydro-4-(N-phenylacetamido)quinaldine; N-(1-acetyl-6-bromo-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-acetamide; N-(1-acetyl-1,2,3,4-tetrahydro-2-methyl-6-nitro-4-quinolyl)-acetanilide; N-(1-acetyl-6-chloro-1,2,3,4-tetrahydro-2-methyl-4-quinolyl)-acetanilide; N-(1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-acetamide; N-(1-benzoyl-6-bromo-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-acetamide; N-(1-benzoyl-6-chloro-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-acetamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl- butanamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-fluorobenzoyl)-2-methyl-4-quinolinyl]-hexanamide ; N-[1-(3-chloro-benzoyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide; N-[1-(4-fluoro-benzoyl)-2-methyl-6-nitro-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide; pentanoic acid (1-benzoyl-6-bromo-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-phenyl-amide; N-(1-benzoyl-6-chloro-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-acetamide; N-[6-chloro-1-(4-fluoro-benzoyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide; N-[6-bromo-1-(4-fluoro-benzoyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide; N-(1-benzoyl-6-

nitro-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-acetamide; N-(1-benzoyl-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-butyramide; N-[1-(3-methoxy-benzoyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-2,2-dimethyl-N-phenyl-propionamide.

9. The compound of Claim 8 wherein:

X is $-CHR^2-$;

R^2 is H, methyl or ethyl;

R^3 is an optionally substituted aromatic group; and

R^5 and R^6 are each H.

10. The compound of Claim 9 wherein the compound is represented by the following structural formula:



where Ring **A**, R^1 and R^4 are each independently defined in Claim 8.

11. The compound of Claim 10 wherein:

R^1 is H or an optionally substituted, cycloalkyl group, aromatic group or non-aromatic heterocyclic group;

R^3 is phenyl or $[R^{11}]$-phenyl;

R^4 is H, $-CH_2C(O)R^{14}$, $-CH_2R^{15}$, $-CH_2OR^{14}$ or an optionally substituted, C_1-C_3 alkyl group, cycloalkyl group, aromatic group or non-aromatic heterocyclic group;

R^{14} is H or an optionally substituted, alkyl group, aromatic group, cycloalkyl group or non-aromatic heterocyclic group; and

R^{15} is an optionally substituted, aromatic group, cycloalkyl group or non-aromatic heterocyclic group;

where R^{11} and the optional substituents are each independently defined in Claim 8.

12. The compound of Claim 10 wherein:

Ring **A** is phenyl or [R^{11}]-phenyl, where R^{11} is at the five, six, seven and/or eight position;

R^1 is R^{18}; and

R^4 is R^{18}, C_1-C_4 alkyl, -CH_2OH, -CH_2OCH_3, -$CH_2OCH_2CH_3$, -$CH_2CH_2OCH_3$ or -$CH_2CH_2OCH_2CH_3$; and

R^{18} is an optionally substituted, phenyl, pyridyl, furanyl, thiophenyl, isoxazolyl, imidazolyl, pyrazolyl, pyrrolyl, benzofuranyl, tetrazolyl, thiazolyl, benzyl, benzothiazolyl, benzoimidazolyl, benzotriazolyl, benzomorpholinyl, benzopyrazolyl, indolyl, -CH_2-(*N*-pyridyl), -CH_2-furanyl, -CH_2-thiophienyl, -CH_2-isoxazolyl, -CH_2-imidazolyl, -CH_2-pyrazolyl, -CH_2-pyrollyl, -CH_2-benzofuranyl, -CH_2-tetrazolyl, -CH_2-thiazolyl, -CH_2-tetrazolyl, -CH_2-benzothiazolyl, -CH_2-benzimidazolyl, -CH_2-O-phenyl, -$CH_2C(O)$-phenyl, naphthalimidyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl or cyclopropyl group;

where R^{11} and the optional substituents are each independently defined in Claim 8.

13. The compound of Claim 12 wherein:

Ring **A** is phenyl or [R^{11}]-phenyl, where R^{11} is at the six and/or seven position;

R^1 is phenyl, thiophenyl, furanyl, pyridyl, pyrmidinyl, oxazolyl, isoxazolyl, benzotriazolyl or benzomorpholinyl, each group being optionally substituted with R^{11};

R^3 is [R^{11}]-phenyl; and

R^4 is methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *tert*-butyl, $-CH_2OCH_3$ or $-CH_2OCH_2CH_3$;

where R^{11} is defined in Claim 8.

14. The compound of Claim 12 wherein:

R^1 is thiophenyl, [R^{11}]-thiophenyl, isoxazolyl, [R^{11}]-isoxazolyl, pyridinyl, [R^{11}]-pyridinyl, benzotriazolyl, [R^{11}]-benzotriazolyl, benzomorpholinyl or [R^{11}]-benzomorpholinyl, where R^{11} is defined in Claim 8; or R^1 is phenyl or [R^{11}]-phenyl, where R^{11} is halo, $-OR^o$, $-N(R')_2$, oxazolyl or



;

R^3 is [R^{11}]-phenyl, where R^{11} is Br, Cl, $-CH_3$, $-N(R')_2$, $-NHC(O)OR'$, $-S(O)_2CH_3$, $-S(O)_2N(R')_2$ or $-(CH_2)_yC(O)N(R')_2$; and

R^4 is methyl, ethyl or $-CH_2OCH_3$;

where R^o and R' are each independently defined in Claim 8.

15. The compound of Claim 14 wherein R^3 is [R^{11}]-phenyl, where R^{11} is one substituent at the para position.

16. The compound of Claim 8 wherein:

X is $-CHR^2$; and

R^2 and NR^xR^3 are in a *cis* configuration relative to one another;

where R^2, R^x and R^3 are each independently defined in Claim 8.

17. The compound of Claim 16 where the *cis* configuration is 2S,4R or 2R,4S:



(2*R*, 4*S*)



(2*S*, 4*R*)

18. The compound of claim 8 which is represented by a structural formula selected from the group consisting of:

Structure	Structure
	
	
	
	
	
	
	

Structure	Structure
	
	
	
	
	
	
	

Structure	Structure
	
	
	
	
	
	

Structure	Structure
	
	
	
	
	
	
	

Structure	Structure
	
	
	
	
	
	

or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising the compound of Claim 8 and a pharmaceutically acceptable diluent, excipient or carrier.

20. A method of inhibiting CRTH2 in a subject in need of CRTH2 inhibition, comprising administering to the subject an effective amount of the compound or pharmaceutical salt of Claim 8.

21. A method of inhibiting DP in a subject in need of DP inhibition, comprising administering to the subject an effective amount of the compound or pharmaceutical salt of Claim 8.

22. A method of treating an inflammatory disease, disorder or symptom in a subject in need of the treatment, comprising administering to the subject an effective amount of the compound or pharmaceutical salt of Claim 8.

23. The method of Claim 22, where the inflammatory disease, disorder or symptom is allergic rhinitis, allergic asthma, atopic dermatitis, chronic obstructive pulmonary disorder, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease or a skin disorder.

24. The method of Claim 23, where the inflammatory disease, disorder or symptom is allergic rhinitis or allergic asthma.